Amgen's Repatha Slashes Cardiovascular Event Risk by 31% in High-Risk Patients
AMGN sits 34% above its 52-week low of $261.43.
Summary
Amgen announced highly positive Phase 3 VESALIUS-CV clinical trial results for its drug Repatha, demonstrating a significant 31% reduction in the risk of a first major cardiovascular event, including heart attack, coronary heart disease death, and ischemic stroke, in high-risk patients. This new data is particularly impactful as it applies to patients without known significant atherosclerosis, potentially broadening the drug's addressable market. These strong efficacy results are a material positive for Amgen, strengthening its cardiovascular franchise and indicating a substantial opportunity for increased sales and market share for a key product. Investors will now closely monitor regulatory submissions for label expansion and the subsequent commercial rollout, which could significantly boost Amgen's long-term revenue outlook.
At the time of this announcement, AMGN was trading at $349.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.